#

Dailypharm Live Search Close
  • 3 reimbursed Spinraza use applications from Oct. all cleared
  • by Lee, Hye-Kyung | translator Byun Kyung A | Dec 2, 2020 06:05am
HIRA discloses review cases by Treatment Review and Assessment Committee
Four applications for Soliris all denied
The South Korean health authority has approved of all three cases submitted preliminary approval applications from last month seeking to use spinal muscular atropy (SMA) treatment Spinraza with coverage.

Four months after a reimbursement approval, the drug user has to submit an administration monitoring reports for approval on maintenance dose. And the health authority also granted approval on all 24 cases of the monitoring reports.

On Nov. 30, the Health Insurance Review and Assessment Service (HIRA, President Kim Sun-min) disclosed the results of October cases reviewed by the Treatment Review and Assessment Committee.


One of the most expensive new drugs in the world, Sprinraza costs 92.35 million won per
  • 0
Reader Comment
0
Anonymity comment Write Operate Rule
Colse

´ñ±Û ¿î¿µ¹æ½ÄÀº

´ñ±ÛÀº ½Ç¸í°ÔÀç¿Í À͸í°ÔÀç ¹æ½ÄÀÌ ÀÖÀ¸¸ç, ½Ç¸íÀº À̸§°ú ¾ÆÀ̵𰡠³ëÃâµË´Ï´Ù. À͸íÀº ÇʸíÀ¸·Î µî·Ï °¡´ÉÇϸç, ´ë´ñ±ÛÀº À͸íÀ¸·Î µî·Ï °¡´ÉÇÕ´Ï´Ù.

´ñ±Û ³ëÃâ¹æ½ÄÀº

´ñ±Û ¸í¿¹ÀÚ¹®À§¿ø(ÆÊ-ÄڴϾð-Çʱâ¸ð¾ç ¾ÆÀÌÄÜ)À¸·Î À§ÃËµÈ µ¥Àϸ®ÆÊ ȸ¿øÀÇ ´ñ±ÛÀº ¡®°Ô½ÃÆÇÇü º¸±â¡¯¿Í ¡¯ÆîÃ帱âÇü¡¯ ¸®½ºÆ®¿¡¼­ Ç×»ó ÃÖ»ó´Ü¿¡ ³ëÃâµË´Ï´Ù. »õ·Î¿î ´ñ±ÛÀ» ¿Ã¸®´Â ÀϹÝȸ¿øÀº ¡®°Ô½ÃÆÇÇü¡¯°ú ¡®ÆîÃ帱âÇü¡¯ ¸ðµÎ ÆÊÄڴϾð ȸ¿øÀÌ ¾´ ´ñ±ÛÀÇ ÇÏ´Ü¿¡ ½Ç½Ã°£ ³ëÃâµË´Ï´Ù.

´ñ±ÛÀÇ »èÁ¦ ±âÁØÀº

´ÙÀ½ÀÇ °æ¿ì »çÀü Å뺸¾øÀÌ »èÁ¦ÇÏ°í ¾ÆÀ̵ð ÀÌ¿ëÁ¤Áö ¶Ç´Â ¿µ±¸ °¡ÀÔÁ¦ÇÑÀÌ µÉ ¼öµµ ÀÖ½À´Ï´Ù.

  • ÀúÀ۱ǡ¤ÀÎ°Ý±Ç µî ŸÀÎÀÇ ±Ç¸®¸¦ Ä§ÇØÇÏ´Â °æ¿ì

    »ó¿ë ÇÁ·Î±×·¥ÀÇ µî·Ï°ú °ÔÀç, ¹èÆ÷¸¦ ¾È³»ÇÏ´Â °Ô½Ã¹°

    ŸÀÎ ¶Ç´Â Á¦3ÀÚÀÇ ÀúÀÛ±Ç ¹× ±âŸ ±Ç¸®¸¦ Ä§ÇØÇÑ ³»¿ëÀ» ´ãÀº °Ô½Ã¹°

  • ±Ù°Å ¾ø´Â ºñ¹æ¡¤¸í¿¹¸¦ ÈѼÕÇÏ´Â °Ô½Ã¹°

    ƯÁ¤ ÀÌ¿ëÀÚ ¹× °³Àο¡ ´ëÇÑ ÀνŠ°ø°ÝÀûÀÎ ³»¿ëÀÇ ±Û ¹× Á÷Á¢ÀûÀÎ ¿å¼³ÀÌ »ç¿ëµÈ °æ¿ì

    ƯÁ¤ Áö¿ª ¹× Á¾±³°£ÀÇ °¨Á¤´ë¸³À» Á¶ÀåÇÏ´Â ³»¿ë

    »ç½Ç È®ÀÎÀÌ ¾ÈµÈ ¼Ò¹®À» À¯Æ÷ ½ÃŰ´Â °æ¿ì

    ¿å¼³°ú ºñ¾î, ¼Ó¾î¸¦ ´ãÀº ³»¿ë

    Á¤´ç¹ý ¹× °øÁ÷¼±°Å¹ý, °ü°è ¹ý·É¿¡ ÀúÃ˵Ǵ °æ¿ì(¼±°üÀ§ ¿äû ½Ã Áï½Ã »èÁ¦)

    ƯÁ¤ Áö¿ªÀ̳ª ´Üü¸¦ ºñÇÏÇÏ´Â °æ¿ì

    ƯÁ¤ÀÎÀÇ ¸í¿¹¸¦ ÈѼÕÇÏ¿© ÇØ´çÀÎÀÌ »èÁ¦¸¦ ¿äûÇÏ´Â °æ¿ì

    ƯÁ¤ÀÎÀÇ °³ÀÎÁ¤º¸(Áֹεî·Ï¹øÈ£, ÀüÈ­, »ó¼¼ÁÖ¼Ò µî)¸¦ ¹«´ÜÀ¸·Î °Ô½ÃÇÏ´Â °æ¿ì

    ŸÀÎÀÇ ID ȤÀº ´Ð³×ÀÓÀ» µµ¿ëÇÏ´Â °æ¿ì

  • °Ô½ÃÆÇ Ư¼º»ó Á¦ÇѵǴ ³»¿ë

    ¼­ºñ½º ÁÖÁ¦¿Í ¸ÂÁö ¾Ê´Â ³»¿ëÀÇ ±ÛÀ» °ÔÀçÇÑ °æ¿ì

    µ¿ÀÏ ³»¿ëÀÇ ¿¬¼Ó °ÔÀç ¹× ¿©·¯ ±â»ç¿¡ Áߺ¹ °ÔÀçÇÑ °æ¿ì

    ºÎºÐÀûÀ¸·Î º¯°æÇÏ¿© ¹Ýº¹ °ÔÀçÇÏ´Â °æ¿ìµµ Æ÷ÇÔ

    Á¦¸ñ°ú °ü·Ã ¾ø´Â ³»¿ëÀÇ °Ô½Ã¹°, Á¦¸ñ°ú º»¹®ÀÌ ¹«°üÇÑ °æ¿ì

    µ·¹ú±â ¹× Á÷¡¤°£Á¢ »ó¾÷Àû ¸ñÀûÀÇ ³»¿ëÀÌ Æ÷ÇÔµÈ °Ô½Ã¹°

    °Ô½Ã¹° Àбâ À¯µµ µîÀ» À§ÇØ ³»¿ë°ú ¹«°üÇÑ Á¦¸ñÀ» »ç¿ëÇÑ °æ¿ì

  • ¼ö»ç±â°ü µîÀÇ °ø½ÄÀûÀÎ ¿äûÀÌ ÀÖ´Â °æ¿ì

  • ±âŸ»çÇ×

    °¢ ¼­ºñ½ºÀÇ Çʿ伺¿¡ µû¶ó ¹Ì¸® °øÁöÇÑ °æ¿ì

    ±âŸ ¹ý·ü¿¡ ÀúÃ˵Ǵ Á¤º¸ °ÔÀ縦 ¸ñÀûÀ¸·Î ÇÒ °æ¿ì

    ±âŸ ¿ø¸¸ÇÑ ¿î¿µÀ» À§ÇØ ¿î¿µÀÚ°¡ ÇÊ¿äÇÏ´Ù°í ÆÇ´ÜµÇ´Â ³»¿ë

  • »ç½Ç °ü°è È®ÀÎ ÈÄ »èÁ¦

    ÀúÀÛ±ÇÀڷκÎÅÍ Çã¶ô¹ÞÁö ¾ÊÀº ³»¿ëÀ» ¹«´Ü °ÔÀç, º¹Á¦, ¹èÆ÷ÇÏ´Â °æ¿ì

    ŸÀÎÀÇ ÃÊ»ó±ÇÀ» Ä§ÇØÇϰųª °³ÀÎÁ¤º¸¸¦ À¯ÃâÇÏ´Â °æ¿ì

    ´ç»ç¿¡ Á¦°øÇÑ ÀÌ¿ëÀÚÀÇ Á¤º¸°¡ ÇãÀ§ÀÎ °æ¿ì (ŸÀÎÀÇ ID, ºñ¹Ð¹øÈ£ µµ¿ë µî)

  • ¡ØÀÌ»óÀÇ ³»¿ëÁß ÀϺΠ»çÇ׿¡ Àû¿ëµÉ °æ¿ì ÀÌ¿ë¾à°ü ¹× °ü·Ã ¹ý·ü¿¡ ÀÇÇØ Á¦À縦 ¹ÞÀ¸½Ç ¼öµµ ÀÖÀ¸¸ç, ¹Î¡¤Çü»ç»ó ó¹úÀ» ¹ÞÀ» ¼öµµ ÀÖ½À´Ï´Ù.

    ¡ØÀ§¿¡ ¸í½ÃµÇÁö ¾ÊÀº ³»¿ëÀÌ´õ¶óµµ ºÒ¹ýÀûÀÎ ³»¿ëÀ¸·Î ÆÇ´ÜµÇ°Å³ª µ¥Àϸ®ÆÊ ¼­ºñ½º¿¡ ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì´Â ¼± Á¶Ä¡ ÀÌÈÄ º» °ü¸® ±âÁØÀ» ¼öÁ¤ °ø½ÃÇϰڽÀ´Ï´Ù.

    ¡Ø±âŸ ¹®ÀÇ »çÇ×Àº µ¥Àϸ®ÆÊ ¿î¿µÀÚ¿¡°Ô ¿¬¶ôÁֽʽÿÀ. ¸ÞÀÏ ÁÖ¼Ò´Â dailypharm@dailypharm.comÀÔ´Ï´Ù.

Write
Write
recently Agree DisAgree
If you want to see the full article, please JOIN US (click)